Clinical trial · Observational
Can Quantitative MRI After cTACE Help Predict Survival ?
Can Quantitative MRI After Conventional Transarterial Chemoembolization (cTACE) Help Predict Survival ?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a HCC tumor. Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to quantify the amount of lipiodol delivered to the HCC tumors. In this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to HCC tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI post-TACE | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HCC patients having MRI post-TACE
- description
- HCC patients who have undergone conventional lipiodol based chemoembolization.
- interventionNames
- Other: MRI post-TACE
Primary outcomes (1)
- measure
- Imaging response
- timeFrame
- Every 4-6 weeks during active treatment and then every 3-6 months, up to 5 years or death.
- description
- Imaging response will be assessed according to 3D European Association for the Study of the Liver (EASL) criteria. EASL criteria propose using contrast enhanced (CE) images to measure viable volumes. We will transfer all images to a computer workstation. We will measure 'viable' enhancing tumor volumes at each interval and percent change in viable tumor volume (change from baseline). We will correlate lipiodol delivery measurements to primary outcomes post-therapy.
Secondary outcomes (4)
- measure
- Clinical response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Prospective studies will be performed in 20 patients with Hepatocellular Carcinoma (HCC) independently scheduled to undergo TACE; tumors in each of these candidates will already have been deemed un-resectable. * Reasons may include * concurrent co-morbidities including cardiac or respiratory compromise * recurrent or multi-lobar disease * cirrhosis or portal hypertension * vascular invasion * high tumor burden * contraindications to general anesthesia. * Diagnosis of HCC will have been established by a) biopsy or b) non-invasively, based upon \> 2cm diameter tumor with characteristic imaging findings in the setting of cirrhosis. * Male or female aged 18 to 89 years, all ethnicities Exclusion Criteria: * Infiltrative or diffuse HCC. * Does not meet inclusion criteria. * Pregnant women. * Individuals with pacemakers or other non-MRI compatible metallic implants. * Hemodialysis patients or patients with severely impaired renal function. * Individuals with severe claustrophobia or unwilling to get a MRI.
References
Publications (1)
- DERIVEDGordon AC, Lewandowski RJ, Li W, Zhong X, Kannengiesser SAR, Miller FH, Salem R, Rilling WS, Larson AC, White SB. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation. Radiol Imaging Cancer. 2023 May;5(3):e220019. doi: 10.1148/rycan.220019. PMID 37233207